A randomized, placebo-controlled phase II Trial for patients with relapsing multiple sclerosis
Latest Information Update: 30 May 2024
At a glance
- Drugs OCH NCNP1 (Primary)
- Indications Multiple sclerosis
- Focus First in man; Therapeutic Use
- 18 Apr 2024 Results assessing efficacy and safety presented at the 76th Annual Meeting of the American Academy of Neurology 2024
- 28 Nov 2023 New trial record
- 13 Oct 2023 Results presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis